Exalenz Of Israel, Pfizer Of U.S. In Deal With FDA-Approved Test Kit
This article was originally published in PharmAsia News
Executive Summary
Israel's Exalenz Bioscience has signed a replacement deal with U.S.-based Pfizer to use the BreathID noninvasive diagnostic kit to test Pfizer drugs for treating gastrointestinal disorders
You may also be interested in...
Deal Watch: Amgen BiTEs Back Micromet-Developed Boehringer Antibody
Cancer immunotherapy biotech Leap, backed by HealthCare Ventures and Lilly, reverse-merges with Israel's Macrocure. Elite and SunGen will partner to develop generic versions of four drugs that posted $3bn in aggregate sales over a recent 12-month stretch.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.